Table V.
Relationship between mRNA expression of SBEM and clinicopathological characteristics of breast cancer.
| Group | n | SBEM | t/F | P-value |
|---|---|---|---|---|
| Age, years | 1.768 | 0.0834 | ||
| ≤50 | 25 | 0.50±0.02 | ||
| >50 | 25 | 0.51±0.02 | ||
| Histological classification | 1.767 | 0.837 | ||
| Level 1+level 2 | 26 | 0.49±0.03 | ||
| Level 3 | 24 | 0.50±0.02 | ||
| Tumor size, cm | 1.631 | 0.109 | ||
| ≤2 | 23 | 0.50±0.03 | ||
| >2 | 27 | 0.51±0.01 | ||
| Clinical staging | 2,871.000 | <0.001 | ||
| Phase I | 10 | 0.25±0.01 | ||
| Phase II | 17 | 0.38±0.02 | ||
| Phase III | 14 | 0.40±0.02 | ||
| Phase IV | 9 | 0.97±0.02 | ||
| TNM staging | 2,687 | <0.001 | ||
| T1 | 10 | 0.27±0.01 | ||
| T2 | 18 | 0.35±0.02 | ||
| T3 | 13 | 0.43±0.02 | ||
| T4 | 9 | 0.95±0.02 | ||
| Lymph node metastasis | 135.800 | <0.001 | ||
| No | 40 | 0.30±0.01 | ||
| Yes | 10 | 0.90±0.02 |
SBEM mRNA expression level and age, histological grade, tumor size, clinical stage, TNM stage, lymph node metastasis.